Aspirin Dosing for Clot Prevention

Condition-Specific Dosing Recommendations

The American College of Chest Physicians recommends 75-100 mg daily for long-term prevention of most cardiovascular conditions, including stable angina, unstable angina, and hypertension 1, 2, 4
For transient ischemic attack and ischemic stroke, 50-75 mg daily is recommended for long-term prevention 1, 2
For polycythemia vera, 100 mg daily is recommended 1, 2, 5
For acute conditions such as acute myocardial infarction and acute ischemic stroke, 160 mg daily is recommended 1, 2

The CURRENT-OASIS 7 trial showed that aspirin 75-100 mg/day was equally effective as 300-325 mg/day for preventing stroke, MI, or cardiovascular death in acute coronary syndromes, with a hazard ratio of 0.97 1, 3
The ASA and Carotid Endarterectomy (ACE) trial found that lower doses (81 or 325 mg/day) were more effective than higher doses (650 or 1,300 mg/day) in reducing stroke, MI, or death after carotid endarterectomy, with a p-value of <0.03 1, 2
Controlled trials have demonstrated efficacy with doses as low as 30-50 mg/day for certain conditions, with a moderate strength of evidence 2, 4

Aspirin 100 mg/day is associated with fewer side effects than 300 mg/day, with a significant reduction in gastrointestinal bleeding 3
Aspirin 300 mg/day causes fewer GI side effects than 1,200 mg/day, with a moderate strength of evidence 3
In the CURRENT-OASIS 7 trial, aspirin 75-100 mg/day produced less GI bleeding than 300-325 mg/day, with a hazard ratio of 0.83 3

Enteric-coated aspirin has lower bioavailability and may result in inadequate platelet inhibition at low doses, particularly in heavier individuals, with a high strength of evidence 4, 6
Regular aspirin inhibits platelet function within 1 hour, while enteric-coated formulations may take 3-4 hours to reach peak plasma levels, with a moderate strength of evidence 6

Using unnecessarily high doses (>100 mg) does not provide additional antithrombotic benefit but increases bleeding risk, with a high strength of evidence 1, 3
Assuming one-size-fits-all is not appropriate, as acute situations like myocardial infarction and acute stroke benefit from slightly higher doses (160 mg), with a moderate strength of evidence 1, 2
Overlooking formulation differences can result in inadequate platelet inhibition, and if rapid effect is needed, enteric-coated tablets should be chewed rather than swallowed intact, with a moderate strength of evidence 6